AbbVie reported on Wednesday that a phase 3 trial of its upadacitinib as monotherapy for rheumatoid arthritis (RA) met all of its primary and key secondary endpoints, giving more momentum to the drug that appears poised to help AbbVie retain its share of the RA market after adalimumab biosimilars launch in the United States. However, a death reported during the trial raises renewed concerns about the safety of the Janus kinase inhibitor.
AbbVie reported on Wednesday that a phase 3 trial of its upadacitinib as monotherapy for rheumatoid arthritis (RA) met all of its primary and key secondary endpoints, giving more momentum to the drug that appears poised to help AbbVie retain its share of the RA market after adalimumab biosimilars launch in the United States. However, a death reported during the trial raises renewed concerns about the safety of the Janus kinase (JAK) inhibitor.
The SELECT-MONOTHERAPY clinical trial followed patients with moderate to severe RA who had not responded adequately to treatment with methotrexate. Results at 14 weeks of treatment with once-daily doses of either 15 mg or 30 mg met the study’s primary endpoints of producing a response of ACR20—a 20% improvement by American College of Rheumatology criteria—or low disease activity versus methotrexate therapy. The study found the following at week 14 for patients receiving 15 mg and 30 mg doses of the investigational drug, respectively:
"The positive results from the SELECT-MONOTHERAPY study are encouraging, as they are the first evidence to support the potential of upadacitinib as a therapy without the need for background methotrexate," said Michael Severino, MD.
Serious adverse events (AEs) occurred in 5% and 3% of patients receiving upadacitinib, and AbbVie says that no new safety signals were detected.
However, these positive top-line results are dampened by 1 patient death during the study; a patient had a fatal hemorrhagic stroke, caused by a ruptured aneurysm, while taking the 15-mg dose of the drug. There was also 1 event of pulmonary embolism in the study, occurring in the 15-mg dose group, in a patient with preexisting risk factors for embolism. These results follow a September 2017 report that 2 patients had died in a late-stage trial of upadacitinib, although AbbVie told Reuters at the time that neither death was considered to be related to the investigational drug.
Despite that assurance, JAK inhibitors as a class have come under increased scrutiny; a recent systematic review of the FDA’s Adverse Event Reporting System found elevated reporting for thromboembolic AEs for 2 approved JAK inhibitors, tofacitinib (Xeljanz) and ruxolitinib (Jakafi), and suggested that a class-wide safety issue might exist for JAK inhibitors.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.